Yale researchers, including members of the Colton Center for Autoimmunity at Yale, have uncovered a novel lupus-associated autoantibody that can enhance immune responses against aggressive cancers like glioblastoma.
Yale researchers have uncovered a novel lupus-associated autoantibody that can enhance immune responses against aggressive cancers like glioblastoma. This autoantibody enters tumor cells and binds intracellular RNA, triggering the cGAS pathway and boosting tumor immunity. Published in Science Signaling (March 25, 2025), the study showed that combining this antibody with checkpoint inhibitors significantly improved anti-tumor efficacy in preclinical models
The research was generously funded in part by the Colton Center for Autoimmunity at Yale, which supports innovative autoimmune-related projects. It was led by James Hansen, MD, radiation oncology chief of Yale's Gamma Knife Program, and a member of Yale Cancer Center and the Colton Center. This work exemplifies how cross-disciplinary support—from autoimmunity research to cancer immunotherapy—can yield impactful advances in treatment.
Read the full story from Yale School of Medicine.
.svg)
The Colton Consortium proudly sponsored the 2025 FASEB Autoimmunity Conference in Niagara Falls, a leading international forum advancing autoimmune research and fostering collaboration among scientists and clinicians.
The Colton Center for Autoimmunity at Yale University announced its 2025 award recipients, funding nine translational research projects with nearly $1M to advance diagnostics, treatments, vaccines, and technologies for autoimmune disease.
Penn Medicine’s newly renovated Immune Health facility will house the Penn Colton Center for Autoimmunity—an anchor of the global Colton Consortium—driving bold, cross-disciplinary collaboration to accelerate transformative discoveries in autoimmune disease research.